Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Bawag, Kapsch TrafficCom (17/10/2023)

22.10.2023

Marinomed: Marinomed Biotech AG has taken steps to further increase the flexibility of its corporate financing. Marinomed has agreed on an adjustment of the Convertible Notes Funding Program running since October 2021 (initial maturity September 2023) and its extension until October 2024 with the Swiss investment company Nice & Green S.A. So far, 50% of the original program volume of €5.4 million in convertible bonds have been issued and converted into ordinary shares of Marinomed. In the meantime, the program was paused from July to December 2022 and since March 2023. In order to take the share price, the share liquidity as well as the dilution effect on existing shareholders into account and to secure the ongoing project financing as well, it was agreed to continue the program, but to reduce the tranches from € 300k to € 160k. Also in the future, Marinomed will have the option to suspend the issuance of individual tranches of convertible bonds to react to the actual cash needs of the Company and the situation on the capital markets.
Marinomed Biotech: weekly performance: -6.98%

Bawag: Banking group Bawag published the financial results for the third quarter 2023, reporting a net profit of € 186 million, earnings per share € 2.25, and an RoTCE of 27.6%. The operating performance of our business was strong with pre-provision profits of € 268 million and a cost-income ratio of 31.3%. For the first nine months, Bawag Group reported a net profit of € 506 million, earnings per share of € 6.13, an RoTCE of 24.9%, and a CIR of 31.8%. Anas Abuzaakouk, CEO, commented: “We delivered another record quarterly result with net profit of € 186 million and an RoTCE of 28% for the third quarter. With our strong operating performance, we are on track to deliver a record year of earnings and expect to meet or exceed all 2023 targets despite an overall subdued market and cautious consumer sentiment. We target to complete our recently approved €175 million share buyback program by the end of the year and will address any further capital distributions with year-end results based on current M&A prospects, market developments, and subject to regulatory approvals.'
Bawag: weekly performance: -7.86%

Kapsch TrafficCom: Kapsch TrafficCom announces that it has won the tender to provide direct customer service for the Polish e-TOLL. The contract is worth PLN 62.87 million (as of October 16, 2023: around EUR 14 million) and will run for three years from February 1, 2024. Under the contract, Kapsch will provide customer service for the e-TOLL system at 100 distribution points across Poland. The distribution points will be open all year round and around the clock for motorists.
Kapsch TrafficCom: weekly performance: -3.33%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/10/2023)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Bawag, Kapsch TrafficCom (17/10/2023)


22.10.2023, 2818 Zeichen



Marinomed: Marinomed Biotech AG has taken steps to further increase the flexibility of its corporate financing. Marinomed has agreed on an adjustment of the Convertible Notes Funding Program running since October 2021 (initial maturity September 2023) and its extension until October 2024 with the Swiss investment company Nice & Green S.A. So far, 50% of the original program volume of €5.4 million in convertible bonds have been issued and converted into ordinary shares of Marinomed. In the meantime, the program was paused from July to December 2022 and since March 2023. In order to take the share price, the share liquidity as well as the dilution effect on existing shareholders into account and to secure the ongoing project financing as well, it was agreed to continue the program, but to reduce the tranches from € 300k to € 160k. Also in the future, Marinomed will have the option to suspend the issuance of individual tranches of convertible bonds to react to the actual cash needs of the Company and the situation on the capital markets.
Marinomed Biotech: weekly performance: -6.98%

Bawag: Banking group Bawag published the financial results for the third quarter 2023, reporting a net profit of € 186 million, earnings per share € 2.25, and an RoTCE of 27.6%. The operating performance of our business was strong with pre-provision profits of € 268 million and a cost-income ratio of 31.3%. For the first nine months, Bawag Group reported a net profit of € 506 million, earnings per share of € 6.13, an RoTCE of 24.9%, and a CIR of 31.8%. Anas Abuzaakouk, CEO, commented: “We delivered another record quarterly result with net profit of € 186 million and an RoTCE of 28% for the third quarter. With our strong operating performance, we are on track to deliver a record year of earnings and expect to meet or exceed all 2023 targets despite an overall subdued market and cautious consumer sentiment. We target to complete our recently approved €175 million share buyback program by the end of the year and will address any further capital distributions with year-end results based on current M&A prospects, market developments, and subject to regulatory approvals.'
Bawag: weekly performance: -7.86%

Kapsch TrafficCom: Kapsch TrafficCom announces that it has won the tender to provide direct customer service for the Polish e-TOLL. The contract is worth PLN 62.87 million (as of October 16, 2023: around EUR 14 million) and will run for three years from February 1, 2024. Under the contract, Kapsch will provide customer service for the e-TOLL system at 100 distribution points across Poland. The distribution points will be open all year round and around the clock for motorists.
Kapsch TrafficCom: weekly performance: -3.33%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/10/2023)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #652: Semperit feiert in der Börse, wer feiert mit mir? ATX TR zum Mai-Verfall auf Kurs 6. All-time-High heuer




 

Bildnachweis

Aktien auf dem Radar:FACC, Rosenbauer, AT&S, Amag, Flughafen Wien, Frequentis, Addiko Bank, Rosgix, Palfinger, Pierer Mobility, Erste Group, Österreichische Post, Marinomed Biotech, Gurktaler AG Stamm, Polytec Group, S Immo, Agrana, CA Immo, EVN, Immofinanz, Kapsch TrafficCom, OMV, Telekom Austria, Uniqa, VIG, Wienerberger, Siemens, BMW, Sartorius, DAIMLER TRUCK HLD..., Wal-Mart.


Random Partner

BNP Paribas
BNP Paribas ist eine führende europäische Bank mit internationaler Reichweite. Sie ist mit mehr als 190.000 Mitarbeitern in 74 Ländern vertreten, davon über 146.000 in Europa. BNP Paribas ist in vielen Bereichen Marktführer oder besetzt Schlüsselpositionen am Markt und gehört weltweit zu den kapitalstärksten Banken.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten